VF
PRVB

Virtu Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Virtu Financial’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,775
Closed -$71K – 2451
2022
Q2 		$71K Buy
+17,775
New +$84.3K 0.01% 1022
2021
Q2 		– Sell
-19,657
Closed -$206K – 2253
2021
Q1 		$206K Buy
+19,657
New +$277K 0.01% 1075
2020
Q3 		– Sell
-56,339
Closed -$795K – 1677
2020
Q2 		$795K Buy
+56,339
New +$711K 0.09% 247
2019
Q4 		$401K Buy
+26,924
New +$240K 0.04% 521

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial's PRVB Position: Q3 2022 in Review

Virtu Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2022, closing a stake of 17,775 shares — an estimated $71K sold.

Virtu Financial first reported a position in PRVB in Q4 2019 and held it in 4 quarters. The position peaked at $795K in Q2 2020. 112 funds tracked by Wall St. Rank hold PRVB as of Q3 2022.

  • Virtu Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Virtu Financial sold 17,775 Provention Bio, Inc. Common Stock shares in Q3 2022, an estimated $71K.
  • Virtu Financial first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Virtu Financial's Provention Bio, Inc. Common Stock position peaked at $795K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2022.

Based on Virtu Financial's 13F filing for Q3 2022, filed 7 Nov 2022.